IL-33 promotes type 1 cytokine expression via p38 MAPK in human NK cells.
ADAM17 Protein
/ metabolism
Cell Line
Cytokines
/ metabolism
Humans
Interferon-gamma
/ genetics
Interleukin-1 Receptor-Like 1 Protein
/ metabolism
Interleukin-12
/ metabolism
Interleukin-33
/ metabolism
Killer Cells, Natural
/ metabolism
Phosphorylation
RNA, Messenger
/ genetics
STAT4 Transcription Factor
/ metabolism
Tumor Necrosis Factor-alpha
/ metabolism
p38 Mitogen-Activated Protein Kinases
/ antagonists & inhibitors
GM-CSF
IL-12
NK
TNF
innate lymphoid cell
synergy
Journal
Journal of leukocyte biology
ISSN: 1938-3673
Titre abrégé: J Leukoc Biol
Pays: England
ID NLM: 8405628
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
03
09
2019
revised:
23
01
2020
accepted:
23
01
2020
pubmed:
6
2
2020
medline:
13
8
2020
entrez:
5
2
2020
Statut:
ppublish
Résumé
This study tests the hypothesis that activation of MAPK by physiologically relevant concentrations of IL-33 contributes to enhanced cytokine expression by IL-12 stimulated human NK cells. While IL-33 canonically triggers type 2 cytokine responses, this cytokine can also synergize with type 1 cytokines like IL-12 to provoke IFN-γ. We show that picogram concentrations of IL-12 and IL-33 are sufficient to promote robust secretion of IFN-γ by human NK cells that greatly exceeds resposes to either cytokine alone. Nanogram doses of IL-33, potentially consistent with levels in tissue microenvironments, synergize with IL-12 to induce secretion of additional cytokines, including TNF and GM-CSF. IL-33-induced activation of the p38 MAPK pathway in human NK cells is crucial for enhanced release of IFN-γ and TNF in response to IL-12. Mechanistically, IL-33-induced p38 MAPK signaling enhances stability of IFNG transcripts and triggers A disintegrin and metalloproteinase domain 17 (ADAM17) mediated cleavage of TNF from the cell surface. These data support our hypothesis and suggest that altered sensitivity of NK cells to IL-12 in the presence of IL-33 may have important consequences in diseases associated with mixed cytokine milieus, like asthma and chronic obstructive pulmonary disease.
Identifiants
pubmed: 32017227
doi: 10.1002/JLB.3A0120-379RR
pmc: PMC7229703
mid: NIHMS1586463
doi:
Substances chimiques
Cytokines
0
IL1RL1 protein, human
0
Interleukin-1 Receptor-Like 1 Protein
0
Interleukin-33
0
RNA, Messenger
0
STAT4 Transcription Factor
0
Tumor Necrosis Factor-alpha
0
Interleukin-12
187348-17-0
Interferon-gamma
82115-62-6
p38 Mitogen-Activated Protein Kinases
EC 2.7.11.24
ADAM17 Protein
EC 3.4.24.86
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
663-671Subventions
Organisme : NIDA NIH HHS
ID : DP1 DA038017
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR073228
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI148080
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK107502
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK078392
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL141236
Pays : United States
Organisme : CSRD VA
ID : I01 CX001891
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM063483
Pays : United States
Organisme : NIAMS NIH HHS
ID : P30 AR070549
Pays : United States
Organisme : BLRD VA
ID : I01 BX002347
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI118697
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL119538
Pays : United States
Informations de copyright
©2020 Society for Leukocyte Biology.
Références
J Biol Chem. 2005 Aug 26;280(34):30113-9
pubmed: 15983030
Immunity. 2015 Feb 17;42(2):294-308
pubmed: 25692703
Immunity. 1998 Mar;8(3):275-83
pubmed: 9529145
Annu Rev Immunol. 1995;13:251-76
pubmed: 7612223
Nat Rev Immunol. 2018 Nov;18(11):671-688
pubmed: 30209347
Blood. 2005 Jan 1;105(1):282-8
pubmed: 15345584
Eur J Immunol. 2010 Jun;40(6):1708-17
pubmed: 20213736
Eur J Immunol. 2009 Apr;39(4):1046-55
pubmed: 19266498
Immunology. 2013 Jan;138(1):76-82
pubmed: 23078031
J Physiol. 2015 Dec 15;593(24):5269-82
pubmed: 26365358
Cell Physiol Biochem. 2015;36(6):2237-49
pubmed: 26279429
Immunol Rev. 2019 Jan;287(1):202-225
pubmed: 30565241
Nature. 1997 Feb 20;385(6618):729-33
pubmed: 9034190
Int Immunol. 2008 Aug;20(8):1019-30
pubmed: 18550585
Sci Signal. 2010 Jan 19;3(105):cm1
pubmed: 20086235
Immunol Rev. 2018 Jan;281(1):138-153
pubmed: 29247988
J Immunol. 2006 May 1;176(9):5299-305
pubmed: 16621996
Nat Immunol. 2003 Jun;4(6):503-5
pubmed: 12774069
Nature. 1995 Nov 2;378(6552):88-91
pubmed: 7477296
Curr Opin Virol. 2016 Feb;16:15-23
pubmed: 26590692
J Exp Med. 2018 May 7;215(5):1315-1325
pubmed: 29549113
Mol Immunol. 2017 Aug;88:138-147
pubmed: 28644973
Immunity. 2019 Apr 16;50(4):975-991
pubmed: 30995510
Immunity. 2015 Mar 17;42(3):566-79
pubmed: 25786179
Front Immunol. 2019 Apr 16;10:692
pubmed: 31057533
J Mol Cell Cardiol. 1999 Dec;31(12):2087-99
pubmed: 10640438
Pharmacol Rev. 2016 Jan;68(1):142-67
pubmed: 26721702
J Immunol. 2008 Aug 1;181(3):2056-64
pubmed: 18641343
Curr Opin Immunol. 2017 Feb;44:1-6
pubmed: 27835762
J Allergy Clin Immunol. 2019 Jul;144(1):204-215
pubmed: 30876911
Immunol Rev. 2018 Jan;281(1):154-168
pubmed: 29247993
J Immunol. 2018 Feb 1;200(3):1198-1206
pubmed: 29288203
J Asthma. 2013 Oct;50(8):803-9
pubmed: 23855553
Eur J Immunol. 1997 Nov;27(11):2787-92
pubmed: 9394800
Int J Prev Med. 2017 Aug 31;8:65
pubmed: 28966754
J Am Soc Nephrol. 2017 Jul;28(7):2068-2080
pubmed: 28154198
J Immunol. 1998 Dec 1;161(11):5821-4
pubmed: 9834059
Blood. 2003 Jul 1;102(1):207-14
pubmed: 12637316
Proc Natl Acad Sci U S A. 2016 Sep 6;113(36):10139-44
pubmed: 27551096
J Immunol. 2000 Aug 1;165(3):1374-80
pubmed: 10903740
J Immunol. 1999 Apr 15;162(8):4511-20
pubmed: 10201989
Chest. 2013 Jan;143(1):196-206
pubmed: 23276842
Mol Cell. 2010 Feb 26;37(4):551-66
pubmed: 20188673
ACS Med Chem Lett. 2011 Jun 24;2(8):632-7
pubmed: 24900358